This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dega, H.
Right arrow Articles by Grosset, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dega, H.
Right arrow Articles by Grosset, J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2002, p. 3193-3196, Vol. 46, No. 10
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.10.3193-3196.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Bactericidal Activity of Rifampin-Amikacin against Mycobacterium ulcerans in Mice

Herve Dega, Abdelhalim Bentoucha, Jerome Robert, Vincent Jarlier, and Jacques Grosset*

Faculte de Medecine Pitie-Salpetriere, Service de Bacteriologie et Hygiene, 75634 Paris Cedex 13, France

Received 15 June 2001/ Returned for modification 2 February 2002/ Accepted 9 July 2002

To identify the most active curative treatment of Buruli ulcer, two regimens incorporating the use of rifampin (RIF) were compared with the use of RIF alone in a mouse footpad model of Mycobacterium ulcerans infection. Treatments began after footpad swelling from infection and continued for 12 weeks with five doses weekly of one of the following regimens: (i) 10 mg of RIF/kg alone; (ii) 10 mg of RIF/kg and 100 mg of amikacin (AMK)/kg; and (iii) 10 mg of RIF/kg, 100 mg of clarithromycin (CLR)/kg, and 50 mg of sparfloxacin (SPX)/kg. The activity of each regimen was assessed in terms of the reduction of the average lesion index and acid-fast bacillus (AFB) and CFU counts. All three regimens displayed various degrees of bactericidal activity against M. ulcerans. The ranking of bactericidal activity was found to be as follows: RIF-AMK > RIF-CLR-SPX > RIF. RIF-AMK was able to cure M. ulcerans-infected mice and prevent relapse 26 weeks after completion of treatment. To determine the impact of different rhythms of administration of RIF-AMK on the suppression of M.ulcerans growth, mice were given the RIF-AMK combination for 4 weeks but doses were administered either 5 days a week or twice or once weekly. After completion of treatment, the mice were kept under supervision for 30 additional weeks. M. ulcerans was considered to have grown in the footpad if swelling was visually observed and harvests contained more than 5 x 105 AFB per footpad. The proportion of mice in which growth of M. ulcerans occurred, irrespective of drug dosage, was compared with the control mice to determine the proportion of M. ulcerans killed. Each dosage of RIF-AMK was bactericidal for M. ulcerans (P < 0.001), but the effect was significantly stronger in mice treated 5 days per week. The promising results of RIF-AMK treatment in M. ulcerans-infected mice support the clinical trial that is currently in progress under World Health Organization auspices in Ghana.

* Corresponding author. Mailing address: Johns Hopkins University School of Medicine, Center for Tuberculosis Research, 424 N. Bond St., Baltimore, MD 21231-1001. Phone: (410) 955-3507. Fax: (410) 614-8173. E-mail: jacques_grosset{at}yahoo.com.

Antimicrobial Agents and Chemotherapy, October 2002, p. 3193-3196, Vol. 46, No. 10
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.10.3193-3196.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Chauty, A., Ardant, M.-F., Adeye, A., Euverte, H., Guedenon, A., Johnson, C., Aubry, J., Nuermberger, E., Grosset, J. (2007). Promising Clinical Efficacy of Streptomycin-Rifampin Combination for Treatment of Buruli Ulcer (Mycobacterium ulcerans Disease). Antimicrob. Agents Chemother. 51: 4029-4035 [Abstract] [Full Text]  
  • Lefrancois, S., Robert, J., Chauffour, A., Ji, B., Jarlier, V. (2007). Curing Mycobacterium ulcerans Infection in Mice with a Combination of Rifampin-Streptomycin or Rifampin-Amikacin. Antimicrob. Agents Chemother. 51: 645-650 [Abstract] [Full Text]  
  • Ji, B., Lefrancois, S., Robert, J., Chauffour, A., Truffot, C., Jarlier, V. (2006). In Vitro and In Vivo Activities of Rifampin, Streptomycin, Amikacin, Moxifloxacin, R207910, Linezolid, and PA-824 against Mycobacterium ulcerans.. Antimicrob. Agents Chemother. 50: 1921-1926 [Abstract] [Full Text]  
  • Goto, M., Nakanaga, K., Aung, T., Hamada, T., Yamada, N., Nomoto, M., Kitajima, S., Ishii, N., Yonezawa, S., Saito, H. (2006). Nerve Damage in Mycobacterium ulcerans-Infected Mice: Probable Cause of Painlessness in Buruli Ulcer. Am. J. Pathol. 168: 805-811 [Abstract] [Full Text]  
  • Etuaful, S., Carbonnelle, B., Grosset, J., Lucas, S., Horsfield, C., Phillips, R., Evans, M., Ofori-Adjei, D., Klustse, E., Owusu-Boateng, J., Amedofu, G. K., Awuah, P., Ampadu, E., Amofah, G., Asiedu, K., Wansbrough-Jones, M. (2005). Efficacy of the Combination Rifampin-Streptomycin in Preventing Growth of Mycobacterium ulcerans in Early Lesions of Buruli Ulcer in Humans. Antimicrob. Agents Chemother. 49: 3182-3186 [Abstract] [Full Text]  
  • Wansbrough-Jones, M., Phillips, R. (2005). Buruli ulcer. BMJ 330: 1402-1403 [Full Text]  
  • Okenu, D. M. N., Ofielu, L. O., Easley, K. A., Guarner, J., Spotts Whitney, E. A., Raghunathan, P. L., Stienstra, Y., Asamoa, K., van der Werf, T. S., van der Graaf, W. T. A., Tappero, J. W., Ashford, D. A., King, C. H. (2004). Immunoglobulin M Antibody Responses to Mycobacterium ulcerans Allow Discrimination between Cases of Active Buruli Ulcer Disease and Matched Family Controls in Areas Where the Disease Is Endemic. CVI 11: 387-391 [Abstract] [Full Text]  
  • Rondini, S., Mensah-Quainoo, E., Troll, H., Bodmer, T., Pluschke, G. (2003). Development and Application of Real-Time PCR Assay for Quantification of Mycobacterium ulcerans DNA. J. Clin. Microbiol. 41: 4231-4237 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»